Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology
- PMID: 24563274
- PMCID: PMC4110404
- DOI: 10.1007/s10096-014-2062-6
Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology
Abstract
This review evaluates the serotype epidemiology of complicated pneumococcal pneumonia (CPP) during the period 1990-2012. PubMed and EMBASE were searched using the terms "empyema", "complicated pneumonia", "pleural infection", "necrotizing pneumonia", "pleural effusion", "parapneumonic effusion", "pneumatocele", or "lung abscess"; "pneumococcal" or "Streptococcus pneumoniae"; and "serotype" for studies on the epidemiology of complicated pneumonias published from January 1, 1990 to October 1, 2013. Studies with data on incidence and serotypes were included; reviews, case reports, and conference abstracts were excluded. Of 152 papers, 84 fitted the inclusion criteria. A few pneumococcal serotypes were predominant causes of CPP, particularly serotypes 1, 19A, 3, 14, and 7F. CPP was a more common manifestation of pneumococcal disease among older (>2 years old) than younger children. The data support increases in both reported incidence rates and proportions of CPP in children and adults during the period 1990-2012; specific increases varied by geographic region. The proportions of serotype 3 and, particularly in Asia, serotype 19A CPP have increased, whereas most studies show declines in serotype 14. Serotype 1 has been a predominant cause of CPP since 1990, while antibiotic resistance was infrequent among serotype 1 isolates. The reported incidence and proportions of CPP among pneumonia cases steadily increased from 1990 to 2012. Several factors might account for these increases, including enhanced disease detection due to a higher index of suspicion, more sophisticated diagnostic assays, and changes in the prevalence of serotypes with capacity to invade the pleural space that were not targeted by the 7-valent pneumococcal conjugate vaccine (PCV7).
Similar articles
-
Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany.Vaccine. 2020 Jan 16;38(3):570-577. doi: 10.1016/j.vaccine.2019.10.056. Epub 2019 Nov 14. Vaccine. 2020. PMID: 31735502
-
Capsular serotypes and antimicrobial susceptibilities of Streptococcus pneumoniae causing invasive pneumococcal disease from 2009-2012 with an emphasis on serotype 19A in bacteraemic pneumonia and empyema and β-lactam resistance.Int J Antimicrob Agents. 2013 Nov;42(5):395-402. doi: 10.1016/j.ijantimicag.2013.07.017. Epub 2013 Sep 6. Int J Antimicrob Agents. 2013. PMID: 24071028
-
Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine.Infect Dis (Lond). 2016 Oct;48(10):749-53. doi: 10.1080/23744235.2016.1192720. Epub 2016 Jun 20. Infect Dis (Lond). 2016. PMID: 27320108
-
Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.Int J Infect Dis. 2010 Mar;14(3):e197-209. doi: 10.1016/j.ijid.2009.05.010. Epub 2009 Aug 22. Int J Infect Dis. 2010. PMID: 19700359 Review.
-
Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance.J Korean Med Sci. 2013 Jan;28(1):4-15. doi: 10.3346/jkms.2013.28.1.4. Epub 2013 Jan 8. J Korean Med Sci. 2013. PMID: 23341706 Free PMC article. Review.
Cited by
-
A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies.mBio. 2021 Jun 29;12(3):e0080021. doi: 10.1128/mBio.00800-21. Epub 2021 Jun 1. mBio. 2021. PMID: 34061603 Free PMC article.
-
Hospital-based sentinel surveillance for Streptococcus pneumoniae and other invasive bacterial diseases in India (HBSSPIBD): design and methodology.BMJ Open. 2020 Apr 8;10(4):e034663. doi: 10.1136/bmjopen-2019-034663. BMJ Open. 2020. PMID: 32273315 Free PMC article.
-
Disease burden and high-risk populations for complications in patients with acute respiratory infections: a scoping review.Front Med (Lausanne). 2024 May 16;11:1325236. doi: 10.3389/fmed.2024.1325236. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38818396 Free PMC article.
-
Predictors and Clinical Outcomes in Empyema Thoracis Patients Presenting to the Emergency Department Undergoing Video-Assisted Thoracoscopic Surgery.J Clin Med. 2019 Oct 3;8(10):1612. doi: 10.3390/jcm8101612. J Clin Med. 2019. PMID: 31623408 Free PMC article.
-
Streptococcus pneumoniae serotype 3 genotypes in invasive isolates from Colombia.Biomedica. 2021 Jun 29;41(2):338-346. doi: 10.7705/biomedica.5407. Biomedica. 2021. PMID: 34214273 Free PMC article.
References
-
- World Health Organization (WHO) 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec. 2008;83:373–384. - PubMed
-
- World Health Organization (WHO) (2009) Acute respiratory infections (update February 2009). Available online at: http://apps.who.int/vaccine_research/diseases/ari/en/. Accessed 22 November 2013
-
- Spencer DA, Cliff D. The changing epidemiology of parapneumonic empyema in children. Paediatr Child Health. 2008;18:513–518. doi: 10.1016/j.paed.2008.07.013. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources